MNKD Stock: Insider Activity, Filings & Research

MannKind Corporation (MNKD) — Drillr’s hub for MNKD insider activity, SEC filings, earnings signals and AI research. Over the trailing 3 months, MNKD insiders filed 1 open-market buy and 2 sales (SEC Form 4).

Sentiment

83/100

Buys (3m)

Sells (3m)

Net (3m)

$193.3K

Insiders buying

Insider trades by month Buys Sells

Sep

Nov

Dec

Jan

Mar

May

Context3-month price +13.9%Institutions accumulating (13F)

Date	Insider	Type	Shares	Price
May 22, 2026	Grancio Jenniferdirector	Grant	82,781	—
May 22, 2026	Consiglio Ronald Jdirector	Grant	16,556	—
May 22, 2026	HOOPER ANTHONY Cdirector	Grant	16,556	—
May 22, 2026	Consiglio Ronald Jdirector	Grant	82,781	—
May 22, 2026	Binder Steven B.director	Grant	82,781	—
May 22, 2026	Tross Stuart Aofficer: Chief People & Workpl Officer	Grant	33,898	$2.95
May 22, 2026	HOOPER ANTHONY Cdirector	Grant	82,781	—
May 22, 2026	Marasco Dominicofficer: Pres, Endocrine Business Unit	Grant	8,474	$2.95
May 22, 2026	Consiglio Ronald Jdirector	Grant	10,000	$2.95
May 22, 2026	Friedman Michael Adirector	Grant	82,781	—
May 22, 2026	Shannon James Samueldirector	Grant	82,781	—
May 22, 2026	MUNDKUR CHRISTINEdirector	Grant	82,781	—
May 22, 2026	Kay Sabrinadirector	Grant	82,781	—
May 22, 2026	Shannon James Samueldirector	Grant	16,556	—
May 13, 2026	Thomson Davidofficer: EVP Genl Counsel & Secretary	Tax	12,387	$3.52

Source: MNKD SEC Form 4 filings, latest May 22, 2026. For informational purposes only — not investment advice.

Overview

MannKind Corporation (NASDAQ:MNKD) is a biopharmaceutical company founded in 1991 and headquartered in Westlake Village, California. The company has transformed from a single-product diabetes-focused entity into a diversified biopharmaceutical company with multiple revenue streams. MannKind specializes in developing and commercializing inhaled therapeutic products using its proprietary Technosphere drug delivery platform, primarily targeting endocrine disorders and orphan lung diseases. The company went public in 2004 and has evolved significantly over the past two decades, particularly accelerating its diversification strategy since 2022.

Business

MannKind operates in the biopharmaceutical industry, focusing on inhaled drug delivery systems for treating diabetes and rare lung diseases. The company's core technology is the Technosphere platform, a proprietary inhalable microparticle system that enables rapid drug absorption through the lungs, offering an alternative to traditional injection-based therapies. The company operates across three main business segments: 1. Endocrine/Diabetes Products (approximately 25% of revenue): MannKind markets Afrezza, an inhaled insulin for adults with diabetes that provides rapid-acting glucose control within minutes of inhalation. Unlike traditional insulin injections, Afrezza mimics the body's natural insulin response more closely. The company also sells V-Go, a wearable insulin delivery device acquired in 2022, and promotes Thyquidity, a liquid levothyroxine for hypothyroidism treatment. 2. Royalty and Manufacturing Services (approximately 45% of revenue): The company's largest revenue contributor comes from its partnership with United Therapeutics for Tyvaso DPI (dry powder inhaler), an inhaled treatment for pulmonary arterial hypertension. MannKind receives 10% royalties on net sales and provides manufacturing services, generating over $100 million annually from this partnership alone. 3. Pipeline Development and Collaboration Services (approximately 30% of revenue): MannKind develops new inhaled therapies including MNKD-101 (clofazimine for nontuberculous mycobacterial lung infections) and MNKD-201 (nintedanib for idiopathic pulmonary fibrosis). The company also provides drug development and manufacturing services to other pharmaceutical companies.

Revenue model

MannKind generates revenue through multiple business models. The primary revenue streams include product sales of diabetes medications (Afrezza, V-Go, Thyquidity), royalty payments from licensing agreements, manufacturing service fees, and collaboration revenue from development partnerships. The company's largest revenue contributor is the royalty arrangement with United Therapeutics, where MannKind receives 10% of Tyvaso DPI net sales, which exceeded $1 billion in the previous four quarters. This partnership also includes manufacturing services revenue. The diabetes product portfolio generates revenue through direct sales to wholesalers and pharmacies, with Afrezza representing the core proprietary product. Several factors influence MannKind's margins and profitability. Positive margin drivers include the high-margin royalty revenue from Tyvaso DPI, which requires minimal ongoing investment once established, and the scalable nature of the Technosphere manufacturing platform. The company's manufacturing efficiency improvements have increased capacity by 250% in recent years. Margin pressures come from substantial research and development investments in pipeline programs, regulatory compliance costs for multiple clinical trials, and the competitive diabetes market requiring significant marketing and education investments. The company's financial performance is also sensitive to external factors including healthcare reimbursement policies affecting diabetes medication coverage, regulatory approval timelines for new indications, and the competitive landscape in both diabetes and rare lung disease markets. Manufacturing capacity constraints could limit growth, while successful clinical trial outcomes could dramatically expand addressable markets, particularly in the orphan drug space where premium pricing is often sustainable.

Competitive moat

MannKind's competitive moat centers on its proprietary Technosphere drug delivery platform, which provides a moderate but meaningful competitive advantage. The technology enables rapid drug absorption through inhalable microparticles, creating a unique delivery mechanism that differentiates its products from traditional injection-based therapies. The company holds intellectual property protection extending from 2030 to 2043 across various applications, providing a substantial patent runway. The company's strongest moat element is its exclusive manufacturing and royalty relationship with United Therapeutics for Tyvaso DPI, which has become a billion-dollar product. This partnership creates a stable, high-margin revenue stream that would be difficult for competitors to replicate given the established regulatory approvals and manufacturing expertise required. However, MannKind's moat faces several challenges. In the diabetes market, the company competes against well-established insulin products from pharmaceutical giants like Novo Nordisk, Eli Lilly, and Sanofi, which have significantly larger marketing budgets and established physician relationships. Afrezza's market penetration remains limited despite being on the market for nearly a decade, suggesting the inhaled insulin concept faces adoption barriers. The pipeline programs in orphan lung diseases offer stronger moat potential due to smaller addressable markets and higher barriers to entry. Success with MNKD-101 for nontuberculous mycobacterial infections or MNKD-201 for idiopathic pulmonary fibrosis could establish dominant positions in these specialized therapeutic areas. However, these programs face typical biotech risks including clinical trial failures and regulatory setbacks. Overall, MannKind possesses a moderate moat strengthened by its platform technology and key partnerships, but faces significant competitive pressures in its core diabetes market.

Risks & safety

MannKind demonstrates a moderate margin of safety with improving but still evolving financial fundamentals. • Liquidity and Solvency: Strong cash position of $198 million as of Q1 2025, providing substantial runway. Current ratio of 2.36 indicates solid short-term liquidity. However, the company maintains negative stockholders' equity of approximately -$59 million due to accumulated losses, though this is improving with recent profitability. • Cash Flow and Profitability: The company achieved positive net income of $28 million in 2024 and $13 million in Q1 2025, marking a significant turnaround from historical losses. Free cash flow turned positive at $33 million for 2024, though Q1 2025 showed slight negative free cash flow of -$7 million due to seasonal working capital changes. • Valuation Metrics: Trading at 29x trailing P/E ratio and 14.2x EV/EBITDA, which appears reasonable for a profitable biotech with growth prospects. The Graham net-net value remains negative, reflecting the accumulated deficit structure typical of development-stage biotechs. • Debt Management: The company has successfully reduced debt principal by $236 million in 2024 and maintains manageable debt levels relative to its cash position and revenue-generating capacity. • Other Considerations: Revenue diversification across royalties, product sales, and services reduces single-point-of-failure risk. The Tyvaso DPI royalty stream provides stable, predictable income that supports the overall financial foundation.

Recent development

MannKind has undergone significant strategic transformation over the past few years, evolving from a single-product diabetes company into a diversified biopharmaceutical entity. The most significant development was the Tyvaso DPI partnership with United Therapeutics, which began generating substantial royalty revenue and has become the company's largest revenue contributor, exceeding $100 million annually. In the diabetes portfolio, the company has expanded beyond Afrezza through the acquisition of V-Go in 2022 and the addition of Thyquidity promotion rights. More importantly, MannKind is preparing for a major catalyst with Afrezza's pediatric expansion, having completed the INHALE-1 pediatric study and planning to file for pediatric approval in mid-2025. The company has also filed for adult label changes with improved dosing convenience and is exploring gestational diabetes applications. The pipeline development represents the most ambitious expansion of MannKind's strategy. MNKD-101 (clofazimine inhalation suspension) for nontuberculous mycobacterial lung infections has advanced to Phase 3 trials with FDA Fast Track designation, targeting a market expected to exceed $1 billion by decade-end. The company has activated 85% of trial sites across four countries and aims to complete enrollment by year-end 2025. MNKD-201 (inhaled nintedanib) for idiopathic pulmonary fibrosis completed Phase 1 safety studies and is advancing to Phase 2/3 development. This program targets the significant unmet need in IPF treatment by potentially reducing the gastrointestinal side effects associated with current oral therapies. The company has also strengthened its manufacturing capabilities, moving production to its Danbury facility and increasing efficiency by 250% to support both current products and pipeline expansion. Recent collaborations include partnerships with Amphastar for pediatric Afrezza development and NRx Pharmaceuticals for ZYESAMI development, demonstrating the versatility of the Technosphere platform.

MNKD company profile · for informational purposes only — not investment advice.

Track MNKD with Drillr

SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.

Try Drillr for free